

QUANTITY LIMIT CRITERIA

DRUG CLASS	INSOMNIA AGENTS**
BRAND NAME (generic)	<p>AMBIEN (zolpidem)</p> <p>AMBIEN CR (zolpidem extended-release)</p> <p>(flurazepam)</p> <p>DORAL (quazepam)</p> <p>(estazolam)</p> <p>HALCION (triazolam)</p> <p>LUNESTA (eszopiclone)</p> <p>RESTORIL and all temazepam containing Rx products (temazepam)</p> <p>ROZEREM (ramelteon)</p> <p>SONATA (zaleplon)</p>
Status: CVS Caremark Criteria	
Type: Quantity Limit	

** Edluar, Intermezzo, Zolpimist and Belsomra are not included in these criteria. Refer to Insomnia Agents (Edluar, Intermezzo, Zolpimist) PA or Insomnia Agents (Belsomra) PA.

POLICY

FDA-APPROVED INDICATIONS

Ambien

Insomnia Limit Policy 05-2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

Ambien is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Ambien has been shown to decrease sleep latency for up to 35 days in controlled clinical studies. The clinical trials performed in support of efficacy were four to five weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.

Ambien CR

Ambien CR is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration.

Flurazepam

Flurazepam hydrochloride capsules, USP are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Since insomnia is often transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient.

Doral

Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Doral has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Doral has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Doral tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered.

Estazolam

Estazolam is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both outpatient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance. Because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks.

Halcion

Halcion is indicated for the short-term treatment of insomnia (generally 7 to 10 days). Use for more than two to three weeks requires complete re-evaluation of the patient. Prescriptions for Halcion should be written for short-term use (7 to 10 days) and it should not be prescribed in quantities exceeding a one-month supply.

Lunesta

Lunesta is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, Lunesta administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency and maintenance were performed at four weeks in the six-week study (adults only), at the end of both two-week studies (elderly only) and at the end of the six-month study (adults only).

Restoril

Restoril is indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Restoril should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were two weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.

Rozerem

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6 week studies (adults and elderly), and at the end of the 6 month study (adults and elderly).

Sonata

Sonata is indicated for the short-term treatment of insomnia. Sonata has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies. It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to five weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment.

LIMIT CRITERIA

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed. Accumulation does not apply if limit is coded for daily dose.

Drug	1 Month Limit*	3 Month Limit*
Ambien all strengths (zolpidem)	15 tablets/25 days	45 tablets/75 days
Ambien CR all strengths (zolpidem extended-release)	15 tablets/25 days	45 tablets/75 days
Flurazepam all strengths	15 capsules/25 days	45 capsules/75 days
Doral all strengths (quazepam)	15 tablets/25 days	45 tablets/75 days
Estazolam all strengths	15 tablets/25 days	45 tablets/75 days
Halcion all strengths (triazolam)	10 tablets/25 days	30 tablets/75 days
Lunesta all strengths (eszopiclone)	15 tablets/25 days	45 tablets/75 days
Restoril all strengths (temazepam)	15 capsules/25 days	45 capsules/75 days
Rozerem all strengths (ramelteon)	15 tablets/25 days	45 tablets/75 days
Sonata all strengths (zaleplon)	15 capsules /25 days	45 capsules /75 days

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

However due to the abuse potential of these products, it is not recommended to allow these products to be filled at mail

REFERENCES

1. Ambien [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2017.
2. Ambien CR [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2017.
3. Flurazepam [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; November 2014.
4. Doral [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; October 2016.
5. Halcion [package insert]. New York, NY: Pharmacia and Upjohn Company; December 2016.
6. Lunesta [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; May 2014.
7. Estazolam [package insert]. Sellersville, PA: Teva Pharmaceuticals USA; December 2015.
8. Restoril [package insert]. Hazelwood, MO: Mallinckrodt Inc.; April 2016.
9. Rozerem [package insert]. Deerfield, IL: Takeda Pharmaceuticals American Inc.; November 2010.
10. Sonata [package insert]. Bristol, TN: King Pharmaceuticals Inc.; November 2016.
11. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically.
www.micromedexsolutions.com [available with subscription]. Accessed May 2017.
12. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.;
http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed May 2017.
13. National Institutes of Health. NIH State-of-the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Volume 22, Number 2. June 13-15, 2005.
14. Silber, MH. Chronic Insomnia. *N Engl J Med*. 2005; 353: 803-810.
15. Krystal, AD. The Changing Perspective on Chronic Insomnia Management. *J Clin Psychiatry*. 2004; 65(S8): 20-25.
16. Ramakrishnan K, Scheid DC. Treatment Options for Insomnia. *American Family Physician*. August 15, 2007; 76(4):517-527.
17. Schutte-Rodin S; Broch L; Buysse D; Dorsey C; Sateia M. Clinical Guideline for the Evaluation and management of Chronic Insomnia in Adults. *J Clin Sleep Med* 2008;4(5):487-504.
18. Morgenthaler T; Kramer M; Alessi C et al. Practice Parameters for the Psychological and Behavioral Treatment of Insomnia: an Update. An American Academy of Sleep Medicine report. *SLEEP* 2006;29(11):1415-1419.
19. Gaseem A, Kansagara D, Forcica MA, Cooke M, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med*. Epub ahead of print May 3, 2016. doi:10.7326/M15-2175.